Liposomal dexamethasone–diclofenac combinations for local osteoarthritis treatment

Elron-Gross, Inbar; Glucksam, Yifat; Margalit, Rimona

doi:10.1016/j.ijpharm.2009.04.025

Cited by 88 publications

(69 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For separation of liposomes like, for hydrophobic drugs, the centrifugation method is widely used. Free ANS was removed from the liposome suspensions, initially by centrifuging at 2000 rpm for 10 min, after which the supernatant liposomal dispersion was centrifuged at 57 438g using a refrigerated centrifuge (Sigma 3K30, Germany) at 4 C for 60 min to precipitate the liposomes (Elron-Gross et al, 2009;Yang et al, 2007a,b,c). Complete precipitation of the liposomes was confirmed by observing the absence of particles in the supernatant, then the supernatant was separated and the liposome pellet washed three times with millipore water.…”

Section: Formulation Of Conventional and Pegylated Liposomesmentioning

confidence: 99%

PEGylated liposomes of anastrozole for long-term treatment of breast cancer:in vitroandin vivoevaluation

Shavi

Reddy

Raghavendra

et al. 2015

Journal of Liposome Research

View full text Add to dashboard Cite

The aim of present study was to develop conventional and PEGylated (long circulating), liposomes containing anastrozole (ANS) for effective treatment of breast cancer. ANS is a third-generation non-steroidal aromatase inhibitor of the triazole class used for the treatment of advanced and late-stage breast cancer in post-menopausal women. Under such disease conditions the median duration of therapy should be prolonged until tumor regression ends (>31 months). Liposomes were prepared by the thin film hydration method by using ANS and various lipids such as soyaphosphatidyl choline, cholesterol and methoxy polyethylene glycol distearoyl ethanolamine in different concentration ratios and evaluated for physical characteristics, in vitro drug release and stability. Optimized formulations of liposome were studied for in vitro cytotoxic activity against the BT-549 and MCF-7 cell lines and in vivo behavior in Wistar rats. Preformulation studies, both Fourier transform infrared study and differential scanning calorimetry analysis showed no interaction between the drug and the excipients used in the formulations. The optimized formulations AL-07 and AL-09 liposomes showed encapsulation efficiencies in the range 65.12 ± 1.05% to 69.85 ± 3.2% with desired mean particle size distribution of 101.1 ± 5.9 and 120.2 ± 2.8 nm and zeta potentials of -43.7 ± 4.7 and -62.9 ± 3.5 mV. All the optimized formulations followed Higuchi-matrix release kinetics and when plotted in accordance with the Korsemeyer-Peppas method, the n-value 0.5 < n < 1.0 suggests an anomalous (non-Fickian) transport. Likewise, the PEGylated liposomes showed greater tumor growth inhibition on BT-549 and MCF-7 cell lines from in vitro cytotoxicity studies (p < 0.05). Pharmacokinetic study of conventional and PEGylated liposomes in Wistar rats demonstrated a 3.33- and 20.28-fold increase in AUC(0-∞) values when compared to pure drug (p < 0.001). Among the formulations, PEGylated liposomes showed encouraging results by way of their long circulation and sustained delivery properties for effective treatment of breast cancer.

show abstract

Section: Formulation Of Conventional and Pegylated Liposomesmentioning

confidence: 99%

PEGylated liposomes of anastrozole for long-term treatment of breast cancer:in vitroandin vivoevaluation

Shavi

Reddy

Raghavendra

et al. 2015

Journal of Liposome Research

View full text Add to dashboard Cite

show abstract

“…In 2001, Trif et al reported a positive effect of human Lactoferrin encapsulated in liposomes in collagen-induced arthritis in mice [91]. Elron-Gross et al reported a reduction of inflammation in a monosodium iodoacetate (MIA) induced OA rat knee after a liposomal dexamethasone and diclofenac combination injection as compared to control assessed by MRI, in 2009 [32,92], and Dong et al found a combination of Cxb incorporated liposomes and HA to be more effective in pain control and cartilage protection than a single Cxb injection, Cxb liposome, and HA treatment alone [93]. Although liposomes are well established, and are effective and biocompatible, IA residence time is relatively short compared to other DDSs [18].…”

Section: Liposomesmentioning

confidence: 99%

Drugs and Polymers for Delivery Systems in OA Joints: Clinical Needs and Opportunities

et al. 2014

View full text Add to dashboard Cite

Osteoarthritis (OA) is a big burden of disease worldwide and one of the most common causes of disability in the adult population. Currently applied therapies consist of physical therapy, oral medication, intra-articular injections, and surgical interventions, with the main goal being to reduce pain and improve function and quality of life. Intra-articular (IA) administration of drugs has potential benefits in OA treatment because it minimizes systemic bioavailability and side effects associated with oral administration of drugs without compromising the therapeutic effect in the joint. However, IA drug residence time is short and there is a clinical need for a vehicle that is able to provide a sustained release long enough for IA therapy to fulfill its promise. This review summarizes the use of different polymeric systems and the incorporated drugs for IA drug delivery in the osteoarthritic joint with a primary focus on clinical needs and opportunities.

show abstract

“…Therefore, to achieve a sustained anti-inflammatory effect, the administrations of drug-encapsulated liposomes (Williams et al 1996;Elron-Gross et al 2009), microspheres (Thakkar et al 2004;Rothenfluh et al 2008) and hydrogels (Hui et al 2007;Aly 2008) have been applied. Biodegradable microspheres (MS) have proven to be very useful drug delivery systems and provide prolonged drug delivery because of sustained release of the microencapsulated material.…”

Section: Original Articlementioning

confidence: 99%

Intra-articular lornoxicam loaded PLGA microspheres: enhanced therapeutic efficiency and decreased systemic toxicity in the treatment of osteoarthritis

Zhang

Huang

2012

Drug Delivery

View full text Add to dashboard Cite

Liposomal dexamethasone–diclofenac combinations for local osteoarthritis treatment

Cited by 88 publications

References 44 publications

PEGylated liposomes of anastrozole for long-term treatment of breast cancer:in vitroandin vivoevaluation

PEGylated liposomes of anastrozole for long-term treatment of breast cancer:in vitroandin vivoevaluation

Drugs and Polymers for Delivery Systems in OA Joints: Clinical Needs and Opportunities

Intra-articular lornoxicam loaded PLGA microspheres: enhanced therapeutic efficiency and decreased systemic toxicity in the treatment of osteoarthritis

Contact Info

Product

Resources

About